SMC Update - August 2016
The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.
Alirocumab (Praluent®) has been accepted for restricted use in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet and other medication, if tolerated. The restriction limits use specialist lipid clinics in patients at high cardiovascular risk. This advice is also contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.
Insulin degludec (Tresiba®) has been accepted for use in the treatment of diabetes mellitus in adults.
Levofloxacin (Quinsair®) has been accepted for restricted use in the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis. The restriction limits use to third line after colistimethate sodium (first line) and tobramycin (second line).
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.
| « Drug Safety Update - August 2016 | NICE Guidance - August 2016 » |
Leave a Comment